Article de revue
Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance
An affordable, highly immunogenic Neisseria meningitidis serogroup A meningococcal conjugate vaccine (PsA—TT) was licensed for use in sub-Saharan Africa in 2009. In 2010, Burkina Faso became the first country to implement a national prevention campaign, vaccinating 11·4 million people aged 1—29 years. The researchers analysed national surveillance data around PsA—TT introduction to investigate the early effect of the vaccine on meningitis incidence and epidemics.
Auteurs
Langues
- Anglais
Année de publication
2012
Journal
The Lancet Infectious Diseases
Volume
10
Type
Article de revue
Catégories
- Prestation de services
Maladies
- Méningite à méningocoques
Pays
- Burkina Faso
Mots-clés
- Suivi de la couverture
- Introduction de nouveaux vaccins
Régions de l'OMS
- Région africaine
